Unnamed: 0,title,date,stock,sentiment
1389133.0,Xencor Reports Initial Dose-Escalation Data From Phase 1 Study Of XmAb In Solid Tumors: 'generally well-tolerated and a confirmed complete response observed at highest dose level tested',2020-05-13 17:09:00-04:00,XNCR,positive
1389134.0,"Xencor Q1 EPS $(0.140) Beats $(0.380) Estimate, Sales $32.385M Beat $15.060M Estimate",2020-05-07 16:09:00-04:00,XNCR,neutral
1389135.0,Xencor And Vir Biotechnology Enter License Agreement For Use Of Xtend XmAb Antibody Technology In Investigational Antibodies To Potentially Treat Coronavirus,2020-03-25 16:01:00-04:00,XNCR,positive
1389136.0,"Barclays Initiates Coverage On Xencor with Underweight Rating, Announces $28 Price Target",2020-03-04 05:37:00-05:00,XNCR,neutral
1389137.0,"Guggenheim Securities Upgrades Xencor to Buy, Announces $43 Price Target",2020-02-25 07:02:00-05:00,XNCR,positive
1389138.0,"Xencor Q4 EPS $(0.47) Misses $(0.41) Estimate, Sales $3.16M Miss $14.27M Estimate",2020-02-24 16:01:00-05:00,XNCR,negative
1389139.0,"Aimmune Therapeutics Reports License Of Exclusive Global Rights To Xencor's XmAb 7195 For Development Of Next-Gen Food Allergy Treatments; Aimmune to Make Upfront Payment To Xencor Of $5M In Cash, $5M In Equity",2020-02-05 08:13:00-05:00,XNCR,positive
1389140.0,"RBC Capital Initiates Coverage On Xencor with Outperform Rating, Announces $44 Price Target",2020-01-30 08:36:00-05:00,XNCR,neutral
1389141.0,Xencor And Gilead Enter License Agreement For Use Of XmAb Antibody Technologies In Investigational Agents For HIV,2020-01-08 08:04:00-05:00,XNCR,positive
1389142.0,"Xencor shares are trading lower after John Stafford a company director sold 212,939 shares at an average price of $39.52 per share. NOTE: When an insider sells shares, the market may perceive it as a sign of weak confidence in the company's outlook.",2019-12-27 09:59:00-05:00,XNCR,positive
1389143.0,"Xencor Q3 EPS $(0.18) Beats $(0.55) Estimate, Sales $21.76M Beat $7.39M Estimate",2019-11-05 16:45:00-05:00,XNCR,neutral
1389144.0,"Canaccord Genuity Maintains Buy on Xencor, Raises Price Target to $52",2019-08-08 07:52:00-04:00,XNCR,neutral
1389145.0,Xencor shares are trading lower after the company reported Q2 earnings results. Multiple firms downgraded the stock following earnings.,2019-08-07 10:44:00-04:00,XNCR,neutral
1389146.0,Guggenheim Downgrades Xencor to Neutral,2019-08-07 06:56:00-04:00,XNCR,neutral
1389147.0,Raymond James Downgrades Xencor to Market Perform,2019-08-07 06:41:00-04:00,XNCR,neutral
1389148.0,"Xencor Q2 EPS $(0.28) Beats $(0.46) Estimate, Sales $19.485M Beat $7.64M Estimate",2019-08-06 16:07:00-04:00,XNCR,neutral
1389149.0,Xencor shares are trading higher after it was announced the company would replace HFF Inc in the S&P SmallCap 600.,2019-06-25 09:40:00-04:00,XNCR,positive
1389150.0,Xencor To Join S&P SmallCap 600,2019-06-24 18:02:00-04:00,XNCR,positive
1389151.0,"Mizuho Initiates Coverage On Xencor with Buy Rating, Announces $52 Price Target",2019-06-13 06:30:00-04:00,XNCR,neutral
1389152.0,Xencor Doses First Patient In Phase 1 Study Of XmAb22841 For The Treatment Of Patients With Advanced Solid Tumors,2019-06-03 08:02:00-04:00,XNCR,positive
1389153.0,"Xencor Q1 EPS $1.38 Up From $(0.62) YoY, Sales $111.939M",2019-05-09 16:11:00-04:00,XNCR,neutral
1389154.0,Xencor Announces Partial Clinical Hold Lifted On Phase 1 Study Of XmAb14045,2019-04-30 08:02:00-04:00,XNCR,neutral
1389155.0,"Guggenheim Initiates Coverage On Xencor with Buy Rating, Announces $42 Price Target",2019-04-12 07:27:00-04:00,XNCR,neutral
1389156.0,Xencor And Astellas Enter Collaboration For Novel Bispecific Antibody Program; Astellas To Receive Exclusive Worldwide License To Potential Drug Candidates,2019-04-02 08:04:00-04:00,XNCR,positive
1389157.0,"Berenberg Initiates Coverage On Xencor with Buy Rating, Announces $45 Price Target",2019-03-27 07:44:00-04:00,XNCR,neutral
1389158.0,"Xencor Inc shares are trading higher after Ronin Capital bought 39,400 shares of the company's stock at an average price of $29.04 per share.",2019-03-20 11:05:00-04:00,XNCR,positive
1389159.0,"Raymond James Initiates Coverage On Xencor with Outperform Rating, Announces $40 Price Target",2019-03-15 07:45:00-04:00,XNCR,neutral
1389160.0,"Xencor Q4 EPS $(0.32) Beats $(0.49) Estimate, Sales $11.564M Beat $5.86M Estimate",2019-02-25 17:33:00-05:00,XNCR,neutral
1389161.0,Nomura Downgrades Xencor to Reduce,2019-02-22 06:54:00-05:00,XNCR,neutral
1389162.0,Xencor shares are trading lower after the company announced a partial clinical hold on its Phase 1 study of XmAb14045 following safety reports which potentially linked two patient deaths to the drug.,2019-02-20 10:57:00-05:00,XNCR,positive
1389163.0,Xencor Announces Partial Clinical Hold On Phase 1 Study Of XmAb14045 Following Safety Reports Submitted On Two Patient Deaths Possibly Related To The Drug,2019-02-20 07:04:00-05:00,XNCR,positive
1389164.0,"Xencor Will Develop, Commercialize Novel IL-15 Immune Activating Cytokines With Genentech, Will Receive $120M Upfront Payment, Up To $180M In Development Milestones",2019-02-05 08:06:00-05:00,XNCR,positive
1389165.0,"Xencor Regains ex-U.S. Commercial Rights To XmAb13676, CD20 x CD3 Bispecific Antibody",2019-01-07 08:07:00-05:00,XNCR,neutral
1389166.0,"Xencor Had $525M In Cash, Cash Equivalents, Marketable Securities At End Of 2018, Says Has Sufficient Cash To Fund R&D Programs, Operations Into 2023",2018-11-05 16:38:00-05:00,XNCR,positive
1389167.0,"Xencor Q3 EPS $0.05 Beats $(0.52) Estimate, Sales $29.039M Up From $7.09M YoY",2018-11-05 16:38:00-05:00,XNCR,neutral
1389168.0,Xencor to Present Initial Data From Phase 1 Study Of XmAb14045 Bispecific Antibody In Acute Myeloid Leukemia At The 2018 ASH Annual Meeting Dec 1-4,2018-11-01 09:08:00-04:00,XNCR,neutral
1389169.0,"UPDATE: Xencor Highlights 'Positive Trend' In XmAb5871 Primary Endpoint, Secondary Endpoint Met, Well Tolerated",2018-10-05 08:08:00-04:00,XNCR,positive
1389170.0,"Xencor Reports Topline Results From Phase 2 Study Of XmAb5871 In Systemic Lupus Erythematosus, Selection Of Late-Breaking Abstract For ACR",2018-10-05 08:07:00-04:00,XNCR,neutral
1389171.0,"Xencor Announces Topline Results From Phase 2 Study Of XmAb5871 In Systemic Lupus Erythematosus; Met Secondary Endpoint, Reported 'Positive Trend' In Primary Endpoint",2018-10-05 08:05:00-04:00,XNCR,positive
1389172.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,XNCR,neutral
1389173.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,XNCR,neutral
1389174.0,"Stocks Which Set New 52-Week High Yesterday, September 12",2018-09-13 09:44:00-04:00,XNCR,neutral
1389175.0,"BTIG Research Assumes Xencor at Buy, Announces Price Target $56",2018-09-10 07:11:00-04:00,XNCR,neutral
1389176.0,"13F From Omega Shows Exited Stake In Acceleron Pharma, Xencor and Shell Midstream Partners",2018-08-14 11:27:00-04:00,XNCR,neutral
1389177.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,XNCR,neutral
1389178.0,Xencor Expects To Have Cash To Fund Research And Development Programs And Operations Into 2023,2018-08-06 16:12:00-04:00,XNCR,neutral
1389179.0,Xencor Q2 EPS $(0.46) Beats $(0.48) Estimate,2018-08-06 16:12:00-04:00,XNCR,neutral
1389180.0,Stocks Which Set New 52-Week Highs Friday,2018-07-23 11:08:00-04:00,XNCR,neutral
1389181.0,Xencor Doses First Patient In Phase 1 Study Of XmAb20717 Dual Checkpoint Inhibitor For The Treatment Of Advanced Solid Tumors,2018-07-12 16:00:00-04:00,XNCR,positive
1389182.0,"BTIG Research Initiates Coverage On Xencor with Buy Rating, Announces $56 Price Target",2018-06-07 06:43:00-04:00,XNCR,neutral
1389183.0,Xencor Q1 EPS $(0.62) Misses $(0.46) Estimate,2018-05-07 16:05:00-04:00,XNCR,negative
1389184.0,Xencor Presents Preclinical Data On XmAb 24306 At AACR: Showed 'engineered complex enhanced the duration and magnitude of T and NK cell proliferation in vitro and in vivo',2018-04-18 09:07:00-04:00,XNCR,neutral
1389185.0,"Leerink Swann Assumes Xencor at Outperform, Announces Price Target $36.00",2018-03-28 08:22:00-04:00,XNCR,neutral
1389186.0,Xencor Shares Move Lower Over Last Few Mins. Despite Circulating Of Positive Recommendation From Agora Financial Newsletter,2018-03-27 11:06:00-04:00,XNCR,negative
1389187.0,Xencor Shares Down 5.2% After Co. Earlier Priced 7.3M Share Public Offering At $31/Share,2018-03-21 13:08:00-04:00,XNCR,positive
1389188.0,Xencor Announces Offering Of 5M Shares,2018-03-19 16:10:00-04:00,XNCR,positive
1389189.0,"Xencor Reports Q4 GAAP EPS $(0.25) May Not Compare To $(0.35) Est., Sales $10.9M vs $6.8M Est.; Says Expects To Have Cash On Hand To Fund R&D Programs, Operations Beyond '20",2018-02-27 16:45:00-05:00,XNCR,positive
1389190.0,Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates,2018-02-26 08:17:00-05:00,XNCR,positive
1389191.0,"Xencor Reports Dosing Of First Patient In Phase 1 Study Of XmAb 18087 Bispecific Tumor Targeting Antibody For Treatment Of Neuroendocrine Tumor, Gastrointestinal Stromal Tumors",2018-02-22 08:13:00-05:00,XNCR,negative
1389192.0,Xencor Doses First Patient in Phase 1 Study of XmAbÂ®18087,2018-02-22 08:02:00-05:00,XNCR,neutral
1389193.0,"Xencor Highlights '18 Priorities, Expected Milestones",2018-01-05 08:06:00-05:00,XNCR,neutral
1389194.0,Xencor Receives a $10M Milestone Payment from Amgen,2017-12-05 08:00:00-05:00,XNCR,neutral
1389195.0,"Cantor Fitzgerald Initiates Coverage On Xencor with Overweight Rating, Announces $33.00 Price Target",2017-11-29 08:39:00-05:00,XNCR,negative
1389196.0,"Xencor Reports Q3 EPS $(0.33) In-line With Est., Sales $7.1M vs $6.32M Est.",2017-11-07 16:42:00-05:00,XNCR,neutral
1389197.0,Xencor Will Present Final Results From Phase 2 Study Of XmAb 5871 In IgG4-Related Disease At ACR Meeting; Says Has Been Accepted For Late-Breaking Abstract Session,2017-10-20 16:01:00-04:00,XNCR,positive
1389198.0,"Xencor Reports Q2 Loss/Share $(0.15) vs. $(0.25) Est., Sales $13.3M vs. $8.18M Est.",2017-08-07 16:24:00-04:00,XNCR,neutral
1389199.0,"Xencor Reports Interim Data From Ongoing, Open-Labeled, Phase 2 Study Of XmAb 5871 In IgG4-Related Disease: 14 of 15 patients (93%) achieved a response to therapy, 12 of them within 2 weeks of first dose",2017-06-16 08:04:00-04:00,XNCR,neutral
1389200.0,Xencor's XmAb5871 Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease,2017-05-11 08:03:00-04:00,XNCR,neutral
1389201.0,"Xencor Reports Q1 EPS $(0.31) vs $(0.24) Est., Sales $4.3M vs $5.73M Est.",2017-05-09 16:44:00-04:00,XNCR,neutral
1389202.0,Nomura Initiates Coverage On Xencor at Neutral,2017-03-02 07:28:00-05:00,XNCR,neutral
1389203.0,"Xencor Sees Ending 2017 with ~$340M in Cash, Cash Equivalents",2017-02-28 16:56:00-05:00,XNCR,neutral
1389204.0,"Xencor Reports Q4 EPS $(0.21) vs $(0.32) Est., Sales $6.44M vs $5.61M Est.",2017-02-28 16:09:00-05:00,XNCR,neutral
1389205.0,PiperJaffray Initiates Coverage on Xencor at Overweight,2016-10-04 06:10:00-04:00,XNCR,negative
1389206.0,"MorphoSys, Xencor Publish Final Results from Phase 1/2a Trial of MOR208 in CLL/SLL at ASH Annual Meeting",2014-12-07 16:22:00-05:00,XNCR,neutral
1389207.0,"Xencor Announces Q2 Revenue $0.8M, EPS -$0.16 - May Not Compare",2014-07-31 16:37:00-04:00,XNCR,neutral
1389208.0,Morning Market Losers ,2014-07-16 09:54:00-04:00,XNCR,negative
1389209.0,Xencor Initiates Phase 1 Study of XmAb7195,2014-05-28 08:06:00-04:00,XNCR,neutral
1389210.0,Adam Feuerstein Tweet:. @CramersShirt Still early but I really like $XNCR,2014-04-17 10:07:00-04:00,XNCR,positive
1389211.0,Benzinga's Top Initiations,2013-12-30 08:41:00-05:00,XNCR,positive
1389212.0,"Xencor Opens for Trade at $5.95, Priced at $5.50/Share",2013-12-03 10:01:00-05:00,XNCR,neutral
